News & Updates
Filter by Specialty:
Lorundrostat may expand treatment toolbox for uncontrolled hypertension
Aldosterone synthase inhibition with lorundrostat confers substantial blood pressure (BP)-lowering benefit in people with uncontrolled hypertension, while having a favourable safety profile, according to data from the phase II Target-HTN trial.
Lorundrostat may expand treatment toolbox for uncontrolled hypertension
29 Sep 2023
Drug monitoring may prevent weight gain in ASD patients taking aripiprazole
A recent study exploring the relationship between aripiprazole pharmacokinetics (PK), side effects, and effectiveness in children and adolescents with autism spectrum disorder (ASD) has found that higher plasma levels correlate with greater weight gain.
Drug monitoring may prevent weight gain in ASD patients taking aripiprazole
27 Sep 2023
Atezolizumab-chemo confers durable survival benefit in ES-SCLC
In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).
Atezolizumab-chemo confers durable survival benefit in ES-SCLC
27 Sep 2023
Calcium-channel blocker use ups glaucoma prevalence
Use of calcium-channel blockers (CCBs) appears to increase the risk of developing glaucoma, suggests a study. In addition, use of systemic beta blockers is associated with lower intraocular pressure (IOP).